Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network.
By 2050, it is estimated that the number of worldwide Alzheimer's disease (AD) patients will quadruple from the current number of 36 million, while no proven disease-modifying treatments are available. At present, the underlying disease mechanisms remain under investigation, and recent studies suggest that the disease involves multiple etiological pathways. To better understand the disease and develop treatment strategies, a number of ongoing studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI) enroll many study participants and acquire a large number of biomarkers from various modalities including demographic, genotyping, fluid biomarkers, neuroimaging, neuropsychometric test, and clinical assessments. However, a systematic approach that can integrate all the collected data is lacking. The overarching goal of our study is to use machine learning techniques to understand the relationships among different biomarkers and to establish a system-level model that can better describe the interactions among biomarkers and provide superior diagnostic and prognostic information. In this pilot study, we use Bayesian network (BN) to analyze multimodal data from ADNI, including demographics, volumetric MRI, PET, genotypes, and neuropsychometric measurements and demonstrate our approach to have superior prediction accuracy.
Industrial Engineering Department, University of Washington, Seattle, WA USA.
Yan
Y
Jin
Department of Radiology, Washington University in St. Louis, St. Louis, MO USA.
Yi
Y
Su
Department of Biostatistics, University of Washington, Seattle, WA USA.
Xiao-Hua
XH
Zhou
Industrial Engineering Department, University of Washington, Seattle, WA USA.
Shuai
S
Huang
ADNI; Alzheimer’s disease; Bayesian network; Heterogeneous; Multimodal biomarkers